Article

Wavefront-guided PRK after previous keratorefractive surgery safe, effective in study

Wavefront-guided PRK in eyes with high aberrations after keratorefractive surgery was highly predictable and safe, with the vast majority of patients within 0.50 D of the intended correction, said Edward Manche, MD, of Stanford University School of Medicine, Stanford, CA.

Wavefront-guided PRK in eyes with high aberrations after keratorefractive surgery was highly predictable and safe, with the vast majority of patients within 0.50 D of the intended correction, said Edward Manche, MD, of Stanford University School of Medicine, Stanford, CA.

The study included 25 eyes of 21 patients. Fourteen patients had undergone a previous LASIK, nine had had radial keratotomy, and two had had PRK. All patients were treated with the VISX S4 excimer laser and the VISX WaveScan aberrometer.

Dr. Manche reported that there was a significant transient hyperopic overshoot 1 month after the treatment, especially in the patients who had undergone a previous LASIK procedure. He reported that 61% of patients had 20/20 or better.

The predictability of the PRK was very good, with 83% of patients within 0.50 D of the intended correction. No complications developed. All eyes had completely re-epithelialized in 7 days and no haze developed.

The safety was excellent. At 6 months, 23% had a one line or greater increase in the best-corrected visual acuity. At this time point, the uncorrected visual acuity had improved to 20/16.

Patients reported resolution of ghosting of vision. The topography was markedly improved with better centration, and there was a significant decrease in total root mean square values and specifically coma.

"We obtained excellent uncorrected visual acuity and best spectacle-corrected visual acuity, with 23% of eyes having an increase of one or more lines of best-corrected vision at 6 months," Dr. Manche said. "The safety and predictability of the procedure were excellent. There was a significant delay in uncorrected and best spectacle-corrected visual recovery. There was a slight reduction in the total root-mean-square values and not change in trefoil or spherical aberration."

Newsletter

Don’t miss out—get Ophthalmology Times updates on the latest clinical advancements and expert interviews, straight to your inbox.

Related Videos
(Image credit: Ophthalmology Times) ASCRS 2025: Mark Lobanoff, MD, on making the move to office-based surgery
Barsha Lal, PhD, discusses the way low dose atropine affects accommodative amplitude and dynamics at the 2025 ARVO meeting
(Image credit: Ophthalmology Times) NeuroOp Guru: When eye findings should prompt neuroimaging in suspected neuro-Behcet disease
At the Association for Research in Vision and Ophthalmology (ARVO) meeting, Katherine Talcott, MD, a retina specialist at Cleveland Clinic, shared her findings on EYP-1901 (EyePoint Pharmaceuticals) in the phase 2 DAVIO study.
Dr. Jogin Desai, founder of Eyestem Research, discusses his research at the Association for Research in Vision and Ophthalmology.
(Image credit: Ophthalmology Times) ASCRS 2025: Michael Rivers, MD, shares his takeaways as a panelist at the inaugural SightLine event
(Image credit: Ophthalmology Times) ASCRS 2025: Karl Stonecipher, MD, on LASIK outcomes using an aspheric excimer laser for high myopia
John Tan talks about an emergency triage framework for retinal artery occlusion at the 2025 Association for Research in Vision and Ophthalmology (ARVO) meeting.
Dr Robert Maloney at the 2025 Controversies in Modern Eye Care meeting
Wendy Lee, MD, MS, at Controversies in Modern Eye Care 2025.
© 2025 MJH Life Sciences

All rights reserved.